

August 12, 2016

The Manager
Listing Department
The National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor
Plot No. C/1, G. Block
Bandra Kurla Complex
Bandra (East), Mumbai - 400 051

Dear Sir/Madam,

Script Code : lykalabs


- Sub : 1. Un audited Standalone Financial Results for the First Quarter ended 30th June, 2016.
2. Un audited Consolidated Financial Results for the First Quarter ended 30th June, 2016.
3. Limited Review Report of the Auditors.

We forward herewith copy of the Unaudited Standalone and Consolidated Financial Results for the First Quarter ended 30th June, 2016 which were adopted by the Board at its meeting held today together with Limited Review Report of Auditors thereon for your information and record.

The meeting commenced at 5 pm and ended at 9 pm.

Thanking you,

Yours faithfully,
For LYKA LABS LIMITED


P. G. HINDIA
COMPANY SECRETARY



Encl : as above

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016

Particulars		Quarter Ended			Rs. In Lakhs
		Previous Period Ended			
		30-Jun-2016 (Unaudited)	31-Mar-2016 (Audited)	30-Jun-2015 (Audited)	31-Mar-2016 9 months (Audited)
1	Income from operations				
	(a) Net Sales/Income from operations (Net of excise duty)	1,309.83	1,745.91	2,503.78	5,447.02
	(b) Other Operating Income	78.36	109.06	72.19	279.94
	Total income from operations (net)	1,388.19	1,854.97	2,575.97	5,726.96
2	Expenses				
	(a) Cost of Materials Consumed	696.55	736.31	948.27	2,345.49
	(b) Purchase of traded goods	110.13	390.31	289.41	908.25
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(157.64)	57.73	411.74	167.57
	(d) Employee benefits expense	237.16	226.32	202.37	658.11
	(e) Depreciation and amortisation expense	89.33	87.30	90.39	264.02
	(f) Other expenses	267.69	274.89	306.36	853.79
	Total expenses	1,243.22	1,772.86	2,248.54	5,197.23
3	Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional items (1-2)	144.97	82.11	327.43	529.73
4	Other Income	14.54	293.67	20.50	1,124.11
5	Profit/(Loss) from ordinary activities before finance cost and exceptional items (3+4)	159.51	375.78	347.93	1,653.84
6	Finance costs	378.22	377.28	446.80	1,144.35
7	Profit/(Loss) from ordinary activities after finance cost but before exceptional items (5-6)	(218.71)	(1.50)	(98.87)	509.49
8	Exceptional items (Net)	(2.16)	(84.92)	124.07	(60.23)
9	Prior Period Adjustments	-	(35.78)	-	87.70
10	Profit/(Loss) from Ordinary Activities before tax (7-8-9)	(216.55)	119.20	25.20	482.02
11	Tax Expenses	-	-	-	-
12	Net Profit/(Loss) from Ordinary activities after tax (10-11)	(216.55)	119.20	25.20	482.02
13	Extraordinary Item (net of tax expenses)	-	-	-	-
14	Net Profit/(Loss) for the period (12+13)	(216.55)	119.20	25.20	482.02
15	Paid up equity share capital (face value Rs.10/- per share)	2,204.00	2,204.00	2,158.00	2,204.00
16	Reserve excluding Revaluation Reserve as per balance sheet of previous accounting year	-	-	-	4,076.01
17 i.	Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised))				
	(a) Basic	(0.99)	0.53	0.10	2.17
	(b) Diluted	(0.99)	0.53	0.10	2.17
17 ii.	Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised))				
	(a) Basic	(0.99)	0.53	0.10	2.17
	(b) Diluted	(0.99)	0.53	0.10	2.17



Cont'd... 2

Notes:

- 1) The above financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12th August, 2016.
- 2) During the quarter the Company has charged Rs. 21.18 lacs to Statement of Profit & Loss, being depreciation on revalued assets.
- 3) During the Quarter the Company has capitalised interest of Rs 20.44 lacs and allocable expenses of Rs 6.27 lacs towards Ankleshwar Unit Expansion/ Upgradation.
- 4) The Company has one Single Segment "Pharmaceuticals".
- 5) Figures for pervious period have been regrouped/ rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED

N.I. GANDHI (DIN:00021530)
Chairman & Managing Director

Mumbai
12-Aug-2016

M. A. PARIKH & CO.

CHARTERED ACCOUNTANTS

Auditor's Report On Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
Board of Directors of Lyka Labs Limited

1. We have reviewed the accompanying statement of 'Un-audited financial results' of Lyka Labs Limited for the quarter ended 30th June, 2016 hereinafter referred to as 'Statement'. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our limited review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, "Engagements to Review Financial Statements" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. **Fixed Deposits:**

The Company has received Order of Company Law Board (CLB) dated 22nd January, 2016, granting extension of time for repayment of Fixed Deposits which matured, upto 31st December, 2015 on or before 30th June, 2016 and Fixed Deposits maturing and claimed, from 1st January, 2016 to 30th September, 2016 on or before 31st March, 2017, failing which the said "Order" shall be deemed cancelled after 31st March, 2017.

During the Quarter Company has paid Rs. 216.68 lacs of Fixed Deposits which matured and claimed before 31st December, 2015. The Company is of the view that Deposits which matured but not claimed till 31st December, 2015 aggregating to Rs. 139.07 lacs have to be paid on or before 31st March, 2017, if claimed.

The additional liability, if any, arising on account of delayed payment/non-payment shall be provided for in the year in which the said liability settled.

4. **Debentures:**

In Respect of Overdue Debentures aggregating to Rs. 900.00 lacs and interest due thereon Rs.82.28 lacs upto 30th June, 2016, The Company has filed a petition with the Company Law Board, seeking extension of time for repayment up to March, 2020.

The liability, if any, arising on account of delayed payment/non-payment shall be provided for in the year in which the said liability settled.



5. Investment In Subsidiaries:

- 5.1 Earlier the Board of Directors at their meeting held on 10th March, 2016 resolved to merge Company's Wholly own Subsidiaries i.e. Lyka Export Limited and Lyka Healthcare Limited with it effective from 1st April, 2015 ("appointed date") under the provision of section 391 to 394 and other applicable provisions, if any, of the Companies Act, 1956 as amended and the corresponding provisions of the Companies Act, 2013 and SEBI circular No. CIR/CFD/CMD/16/2015 dated 30th November, 2015. Since then the "appointed date" of the said merger is postponed to 1st April, 2016 by the Board of Directors at their meeting held on 4th June, 2016. The proposed merger of Lyka Healthcare Limited and Lyka Export Limited with the Company would be in the best interest of the Company, its shareholders, creditors and all other stakeholders.
- 5.2 Though the present book values of the Companies Investments in equity shares of the Companies Subsidiaries i.e. Lyka BDR International Limited, Lyka Healthcare Limited and Lyka Export Limited are lower than their cost of acquisition, keeping in view their long term business synergy and potential, the management is of the opinion that no provision for fall in their values is required to be made at this juncture.

6. Capital Expenditure:

- 6.1 Tangible Project Capital Work-In-Progress Rs. 1,763.00 lacs as on 30th June, 2016, includes allocable indirect expenditure in respect of modernization/expansion of Ankleshwar unit aggregating to Rs. 164.87 lacs (including Interest for the quarter Rs. 20.44 lacs) which is pending allocation to Fixed Assets on completion of the project.
- 6.2 The Company has incurred direct expenditure and allocable indirect expenditure up to 30th June, 2016 in respect of "new product development and applied research" aggregating to Rs. 1,301.03 lacs including finance cost of Rs. 215.68 lacs which is carried forward under "Capital Work in Progress - Intangibles", to be recognized as "Self Generated Intangible Assets" upon successful development of the respective products or to be charged to the Statement of Profit and Loss in the year in which development is abandoned.

During the quarter, the Company has capitalised Rs. 44.87 lacs (includes finance cost of Rs. 5.20 lacs) as "Self Generated Intangible Assets" upon successful development of the respective products.

7. The Inventories held at Ankleshwar unit of Rs. 813.75 lacs have been certified and valued by the management and have been relied upon by the Auditor.
8. Loans and advances include Rs. 229.51 lacs granted to a Company as financial assistance is considered good for recovery by the management.
9. During the earlier period, the Company has recognized revenue by way of insurance claim aggregating to Rs. 270.97 lacs on account of loss of certain fixed assets and materials due to fire. The Company has received on account payments aggregating to Rs. 209.93 lacs and realized Rs. 4.29 lacs by way of sale of scrap arising from loss of such fixed assets. The balance of Rs. 56.75 lacs is considered good for recovery by the Management. The shortfall if any, shall be adjusted in the year in which the claim is finally settled.



10. Exceptional Items represent excess provision no longer required written back of Rs. 2.16 lacs.

11. Depreciation of Rs. 89.33 lacs charged to Statement of Profit and Loss for quarter ended 30th June, 2016 includes Rs. 21.18 lacs being depreciation relating to Revaluation of Fixed Assets carried out in March, 2007.

12. Contingent Liabilities are not provided for in respect of:

12.1 There were demands raised against the Company aggregating to Rs. 680.62 lacs plus interest thereon under the Drug Price Control Order, 1979 by the Government of India which were contested by the Company. In the earlier year, the Company had received recovery notices for recovery of Rs. 2,094.41 lacs to be deposited into "Drug Price Equalisation Account".

The Company has challenged the said notices in the writ petitions before the Hon'ble High Court of Gujarat. The Hon'ble High Court has admitted the writ petitions subject to the Company depositing certain amounts against the said demands. Accordingly the Company has deposited Rs.1,032.45 lacs.

The Company expects favorable outcome in the said writ petitions and hence, the amounts paid have been treated as advances which are considered as good for recovery.

The Impact, if any, of the outcome of the said writ petition when decided shall be accounted.

12.2 The Company has received orders from Sales Tax department raising demands of Rs.85.45 lacs, Rs. 35.66 lacs and Rs. 97.40 against which it has paid under protest Rs. 45.85 lacs, Rs.35.66 lacs and Rs. 12.50 lacs respectively.

12.3 The Company has received an order from Central Excise department raising demand of Rs. 108.75 lacs against which it has paid under protest Rs. 25 lacs.

12.4 The Company has received an order from Income Tax department raising demand of Rs.912.48 lacs against which it has paid under protest Rs. 100.00 lacs.

The Company has filed appeals in respect of all the above matters which are resting with the respective forums.

13. During the previous year, the Company had lodged claim for refund of excess finance costs charged by two banks aggregating to Rs. 57.14 lacs.

Of the above:

- i. Rs. 33.49 lacs relates to prior year(s) which is presented as Prior Period Income of which Rs. 8.26 lacs is recovered during the previous year.
- ii. Rs. 23.65 lacs relating to the period July, 2015 to December, 2015 is adjusted against Finance cost for the quarter.

14. The Company provides gratuity and leave encashment (benefits) based on actuarial valuation as at the end of the accounting period. As regards the provision for benefits for the quarters ended September and December, the Company provides the liability on an estimated basis as per the policy/rules applicable to its employees in this regard. The difference between the liabilities estimated on quarterly basis with the year end liability on actuarial basis will be adjusted during the last quarter of the accounting period.



15. Taxation:

15.1 Current Tax:

In view of loss for the quarter, current tax has not been provided.

15.2 Deferred Tax:

The Company has not recognized Deferred Tax Assets in view of virtual uncertainty of sufficient future taxable income to set off carried forward losses and unabsorbed depreciation.

16. The balances relating to Sundry Debtors, Sundry Creditors, Fixed Deposits, Group Companies and Loans & Advances as on 30th June, 2016 are subject to confirmation and adjustments, if any on reconciliation of accounts. Since the extent to which these balances are subject to confirmation is not ascertainable, the resultant impact of the same on the financial results cannot be presently ascertained and shall be adjusted in the year in which the confirmation process is completed.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, except:

- i. note no. 5.2 relating to AS 13 "Accounting for Investment"
- ii. note no. 6.2 relating to AS 26 "Intangible Assets"
- iii. note no. 7 relating to AS 2 "Valuation of Inventories"
- iv. note no. 15 relating to AS 22 "Accounting for Taxes on Income"

has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For M. A. Parikh & Co
Chartered Accountants
Firm Reg. No. 107556W

Nalin Shah

Partner
Name: Nalin Shah
Membership No. 136978

Place : Mumbai

Date : 12th August, 2016

LYKA LABS LIMITED					
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016					
(Rs.in Lakhs)					
	Particulars	Quarter Ended			Previous Period Ended
		30-06-2016	31-03-2016	30-06-2015	31-03-2016
		(Unaudited)	(Audited)	(Unaudited)	9 Months (Audited)
1	Income from operations				
	(a) Net Sales/Income from operations (Net of excise duty)	2005.52	3273.42	4638.70	12,543.88
	(b) Other Operating Income	112.45	181.76	139.78	497.02
	Total income from operations (net)	2117.97	3455.18	4778.48	13,040.90
2	Expenses				
	(a) Cost of Materials Consumed	696.55	943.70	948.27	2,345.49
	(b) Purchase of traded goods	327.82	912.84	1161.03	4,444.82
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade,	(123.63)	90.21	397.98	252.51
	(d) Employee benefits expense	443.54	402.70	435.18	1,471.19
	(e) Depreciation and amortisation expense	252.51	249.78	260.08	932.46
	(f) Other expenses	532.46	709.80	773.02	2,476.93
	Total expenses	2129.25	3309.03	3975.56	11,923.40
3	Profit/(Loss) from Operations before Other Income, Finance cost and Exceptional Items (1-2)	(11.28)	146.15	802.92	1,117.50
4	Other Income	21.67	16.94	28.03	176.99
5	Profit/(Loss) from ordinary activities before finance cost and exceptional Items (3+4)	10.39	163.09	830.95	1,294.49
6	Finance costs	426.14	450.89	534.12	1,518.84
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional Items (5-6)	(415.75)	(287.80)	296.83	(224.35)
8	Exceptional Items (Net)	0.01	(1,138.57)	(20.94)	738.18
9	Prior Period Items	-	-	-	(123.47)
10	Profit/(Loss) from Ordinary Activities before tax (7+8+9)	(415.76)	(1,426.37)	275.89	390.36
11	Tax Expenses	0.16	251.53	-	18.63
12	Net Profit/(Loss) from Ordinary activities after tax (10-11)	(415.92)	(1,677.90)	275.89	408.99
13	Extraordinary Item (net of tax expenses)	-	-	-	-
14	Net Profit/(Loss) for the period	(415.92)	(1,677.90)	275.89	408.99
15	Share of Profit/(Loss) of associates	-	-	-	-
16	Minority interest	(2.26)	(478.43)	(107.39)	40.30
17	Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates	(413.66)	(1,199.47)	168.50	368.69

Handwritten signature

LYKA LABS LIMITED					
STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016					
(Rs.in Lakhs)					
	Particulars	Quarter Ended			Previous Period Ended
		30-06-2016 (Unaudited)	31-03-2016 (Audited)	30-06-2015 (Unaudited)	31-03-2016 9 Months (Audited)
18	Paid up equity share capital (face value Rs.10/- per share)	2204.00	2204.00	2158.00	2,204.00
19	Reserve excluding Revaluation Reserve as per Balance Sheet of previous accounting year				1,527.19
20	i Earnings Per Share (before extraordinary items) (of Rs 10/-each (not annualised)				
	(a) Basic	(1.89)	(5.45)	0.77	1.65
	(b) Diluted	(1.89)	(5.45)	0.77	1.65
21	ii Earnings Per Share (After extraordinary items) (of Rs 10/-each (not annualised)				
	(a) Basic	(1.89)	(5.45)	0.77	1.65
	(b) Diluted	(1.89)	(5.45)	0.77	1.65

gl

Notes:

- 1) The above financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company along with Limited Review Report carried out by the Auditors at its meeting held on 12th August, 2016.
- 2) During the quarter the Holding Company has charged Rs. 21.18 lacs to Statement of Profit & Loss, being depreciation on revalued assets.
- 3) During the Quarter the Holding Company has capitalised interest of Rs 20.44 lacs and allocable expenses of Rs 6.27 lacs towards Ankleshwar Unit Expansion/ Upgradation.
- 4) The Company has one Single Segment "Pharmaceuticals".
- 5) Figures for pervious period have been regrouped/ rearranged wherever necessary, to conform to the relevant current period classification.

For LYKA LABS LIMITED



N.I. GANDHI (DIN: 00021530)
Chairman & Managing Director

Mumbai
12-Aug-2016



M. A. PARIKH & CO.

CHARTERED ACCOUNTANTS

Auditor's Report On Quarterly Financial Results and Year to Date Financial Results of the Company Pursuant to Clause 41 of the Listing Agreement

To,
Board of Directors of Lyka Labs Limited

1. We have reviewed the accompanying statement of 'Un-audited consolidated financial results' of Lyka Labs Limited for the quarter ended 30th June, 2016 hereinafter referred to as 'Statement' (which includes the Statement of the company's three subsidiaries and one branch reviewed by other auditors and relied upon by us, after making such changes as are considered necessary for incorporation). This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our limited review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, "Engagements to Review Financial Statements" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. **Principals of Consolidation:**

The Consolidated Financial Results relating to Lyka Labs Limited ("The Holding Company") and its subsidiaries (as stated below) ("the group") have been consolidated in accordance with Accounting Standard 21 (AS 21) "Consolidated Financial Statements", except those of "Lyka Animal Healthcare Limited" subsidiary of Lyka Export Limited which is considered by Lyka Export Limited as an Immaterial Subsidiary :

Name of the Subsidiary	Reporting Period	Percentage of Holding
Lyka BDR International Limited	1st April, 2016 to 30 th June, 2016	65.22%
Lyka Exports Limited	1st April, 2016 to 30 th June, 2016	72.80%
Lyka Healthcare Limited	1st April, 2016 to 30 th June, 2016	100%

- (i) The financial results of the Company and its subsidiaries have been consolidated on a line-by-line basis by adding together the book values of like items of Assets, Liabilities, Incomes and Expenses after fully eliminating intra-group balances/transactions.
- (ii) The consolidated financial results have been prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the Company's standalone financial statements.



- (iii) The consolidated financial results are presented, to the extent possible, in the same format as that adopted by the Parent Company for its standalone financial results.

4. Fixed Deposits:

The Holding Company has received Order of Company Law Board (CLB) dated 22nd January, 2016, granting extension of time for repayment of Fixed Deposits which matured, upto 31st December, 2015 on or before 30th June, 2016 and Fixed Deposits maturing and claimed, from 1st January, 2016 to 30th September, 2016 on or before 31st March, 2017, failing which the said "Order" shall be deemed cancelled after 31st March, 2017.

During the Quarter Holding Company has paid Rs. 216.68 lacs of Fixed Deposits which matured and claimed before 31st December, 2015. The Holding Company is of the view that Deposits which matured but not claimed till 31st December, 2015 aggregating to Rs. 139.07 lacs have to be paid on or before 31st March, 2017, if claimed.

The additional liability, if any, arising on account of delayed payment/non-payment shall be provided for in the year in which the said liability settled.

5. Debentures:

The Holding Company has not repaid Overdue Debentures aggregating to Rs. 900.00 lacs and interest due thereon Rs. 82.28 lacs upto 30th June, 2016, The Holding Company has filed a petition with the Company Law Board, seeking extension of time for repayment up to March, 2020.

The liability, if any, arising on account of delayed payment/non-payment shall be provided for in the year in which the said liability settled.

6. Investment In Subsidiaries:

Earlier the Board of Directors of Holding Company at their meeting held on 10th March, 2016 resolved to merge Company's Wholly own Subsidiaries i.e. Lyka Export Limited and Lyka Healthcare Limited with it effective from 1st April, 2015 ("appointed date") under the provision of section 391 to 394 and other applicable provisions, if any, of the Companies Act, 1956 as amended and the corresponding provisions of the Companies Act, 2013 and SEBI circular No. CIR/CFD/CMD/16/2015 dated 30th November, 2015. Since then the "appointed date" of the said merger is postponed to 1st April, 2016 by the Board of Directors at their meeting held on 4th June, 2016. The proposed merger of Lyka Healthcare Limited and Lyka Export Limited with the Company would be in the best interest of the Company, its shareholders, creditors and all other stakeholders.

7. Capital Expenditure:

- 7.1 Tangible Project Capital Work-In-Progress of Holding Company Rs. 1763.00 lacs as on 30th June, 2016, includes allocable indirect expenditure in respect of modernization/expansion of Ankleshwar unit aggregating to Rs. 164.87 lacs (including Interest for the quarter Rs. 20.44 lacs) which is pending allocation to Fixed Assets on completion of the project.



7.2 The Holding Company has incurred direct expenditure and allocable indirect expenditure up to 30th June, 2016 in respect of "new product development and applied research" aggregating to Rs. 1,301.03 lacs including finance cost of Rs. 215.68 lacs which is carried forward under "Capital Work in Progress - Intangibles", to be recognized as "Self Generated Intangible Assets" upon successful development of the respective products or to be charged to the Statement of Profit and Loss in the year in which development is abandoned.

During the quarter, the Company has capitalised Rs. 44.87 lacs (includes finance cost of Rs. 5.20 lacs) as "Self Generated Intangible Assets" upon successful development of the respective products.

8. The Inventories held at Ankleshwar unit of Rs. 813.75 lacs of the Holding Company have been certified and valued by the management and have been relied upon by the Auditor.
9. Loans and advances made by Holding Company include Rs. 229.51 lacs granted to a Company as financial assistance is considered good for recovery by the management.
10. During the earlier period, the Holding Company has recognized revenue by way of insurance claim aggregating to Rs. 270.97 lacs on account of loss of certain fixed assets and materials due to fire. The Holding Company has received on account payments aggregating to Rs. 209.93 lacs and realized Rs. 4.29 lacs by way of sale of scrap arising from loss such of fixed assets. The balance of Rs. 56.75 lacs is considered good for recovery by the Management. The shortfall if any, shall be adjusted in the year in which the claim is finally settled.
11. Exceptional items (Net) for the current quarter ended 30th June, 2016 are as under:

Sr. No.	Particulars	Rs. In lacs Quarter Ended 30 th June, 2016
a)	Provision no longer required written back	(3.68)
b)	Loss on sale of Fixed Assets	3.69
	Total	0.01

Note: Figures in brackets denote items of income nature.

12. Depreciation of Rs. 252.51 lacs charged to Statement of Profit and Loss for quarter ended 30th June, 2016 includes Rs. 21.18 lacs being depreciation relating to Revaluation of Fixed Assets carried out in March, 2007 by the Holding Company.



13. Contingent Liabilities are not provided for in respect of:

- 13.1 There were demands raised against the Holding Company aggregating to Rs. 680.62 lacs plus interest thereon under the Drug Price Control Order, 1979 by the Government of India which were contested by the Company. In the earlier year, the Holding Company had received recovery notices for recovery of Rs. 2,094.41 lacs to be deposited into "Drug Price Equalisation Account".

The Holding Company has challenged the said notices in the writ petitions before the Hon'ble High Court of Gujarat. The Hon'ble High Court has admitted the writ petitions subject to the Holding Company depositing certain amounts against the said demands. Accordingly the Holding Company has deposited Rs.1,032.45 lacs.

The Holding Company expects favorable outcome in the said writ petitions and hence, the amounts paid have been treated as advances which are considered as good for recovery.

The Impact, if any, of the outcome of the said writ petition when decided shall be accounted.

- 13.2 The Holding Company has received orders from Sales Tax department raising demands of Rs.85.45 lacs, Rs. 35.66 lacs and Rs. 97.40 against which it has paid under protest Rs. 45.85 lacs, Rs.35.66 lacs and Rs. 12.50 lacs respectively.
- 13.3 The Holding Company has received an order from Central Excise department raising demand of Rs. 108.75 lacs against which it has paid under protest Rs. 25 lacs.
- 13.4 The Holding Company has received an order from Income Tax department raising demand of Rs.912.48 lacs against which it has paid under protest Rs. 100.00 lacs
The Holding Company has filed appeals in respect of all the above matters which are resting with the respective forums.
14. During the previous year, the Holding Company has lodged claim for refund of excess finance costs charged by two banks aggregating to Rs. 57.14 lacs.

Of the above:

- i. Rs. 33.49 lacs relates to prior year(s) which is presented as Prior Period Income of which Rs. 8.26 lacs is recovered during the previous year.
 - ii. Rs. 23.65 lacs relating to the period July, 2015 to December, 2015 is adjusted against Finance cost for the quarter.
15. The Holding Company provides gratuity and leave encashment (benefits) based on actuarial valuation as at the end of the accounting period. As regards the provision for benefits for the quarters ended September and December, the Holding Company provides the liability on an estimated basis as per the policy/rules applicable to its employees in this regard. The difference between the liabilities estimated on quarterly basis with the year end liability on actuarial basis will be adjusted during the last quarter of the accounting period.



16. Taxation:

16.1 Current Tax:

In view of loss for the quarter, current tax has not been provided except in case of one subsidiary of the group have not provided for Income Tax for the quarter ended 30th June, 2016.

16.2 Deferred Tax:

The Group has not recognized Deferred Tax Assets in view of virtual uncertainty of sufficient future taxable income to set off carried forward losses and unabsorbed depreciation, except in the case of a Subsidiary Company Lyka Healthcare Limited where it has provided Deferred Tax Assets amounting to Rs. 0.16 lacs.

17. The balances relating to Sundry Debtors, Sundry Creditors, Fixed Deposits, Inter-Company and Loans & Advances as on 30th June, 2016 are subject to confirmation and adjustments, if any on reconciliation of accounts. Since the extent to which these balances are subject to confirmation is not ascertainable, the resultant impact of the same on the financial results cannot be presently ascertained and shall be adjusted in the year in which the confirmation process is completed.

Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies, except:

- i. note no. 7.2 relating to AS 26 "Intangible Assets"
- ii. note no. 8 relating to AS 2 "Valuation of Inventories"
- iii. note no. 16 relating to AS 22 "Accounting for Taxes on Income"

has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For M. A. Parikh & Co
Chartered Accountants
Firm Reg. No. 107556W

Partner
Name: Nalin Shah
Membership No. 136978

Place : Mumbai

Date : 12th August, 2016